Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Decrease in Short Interest

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the target of a large drop in short interest in July. As of July 31st, there was short interest totaling 11,313 shares, a drop of 41.4% from the July 15th total of 19,290 shares. Currently, 0.5% of the shares of the stock are sold short. Based on an average daily volume of 16,846 shares, the days-to-cover ratio is currently 0.7 days.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Xenetic Biosciences

An institutional investor recently bought a new position in Xenetic Biosciences stock. DRW Securities LLC bought a new position in Xenetic Biosciences, Inc. (NASDAQ:XBIO) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned about 0.60% of Xenetic Biosciences at the end of the most recent quarter. Hedge funds and other institutional investors own 15.12% of the company’s stock.

Xenetic Biosciences Stock Performance

Shares of XBIO opened at $3.28 on Monday. The company has a market cap of $7.51 million, a price-to-earnings ratio of -2.83 and a beta of 2.10. The stock has a fifty day moving average price of $2.88 and a two-hundred day moving average price of $2.84. Xenetic Biosciences has a 52-week low of $1.90 and a 52-week high of $13.93.

Xenetic Biosciences (NASDAQ:XBIO) last announced its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter. Xenetic Biosciences had a negative net margin of 75.90% and a negative return on equity of 40.62%. The business had revenue of $0.66 million during the quarter.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.